Limits...
NRD1, which encodes nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and MMP3 expression.

Uraoka N, Oue N, Sakamoto N, Sentani K, Oo HZ, Naito Y, Noguchi T, Yasui W - Cancer Sci. (2013)

Bottom Line: Furthermore, nardilysin expression was significantly associated with poorer prognosis (P = 0.0258).The invasiveness of NRD1-knockdown TE1 and TE5 esophageal cancer cell lines was less than that of the negative control siRNA-transfected cell lines.Expression of MMP2 and MMP3 mRNA was significantly lower in NRD1-knockdown TE5 cells than in negative control siRNA-transfected cells.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Pathology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan.

Show MeSH

Related in: MedlinePlus

Quantitative reverse transcription–polymerase chain reaction (qRT-PCR) analysis of NRD1 mRNA and Western blot analysis of nardilysin protein in normal tissue samples, esophageal cancer cell lines, and esophageal squamous cell carcinoma (ESCC) tissue samples. (a) mRNA expression level of NRD1 in 15 types of normal tissue samples, six esophageal cancer cell lines, and two ESCC tissue samples. The units are arbitrary, and NRD1 mRNA expression was calculated by standardization of the expression in normal colon to 1.0. (b) mRNA expression level of NRD1 in four ESCC tissue samples and their non-neoplastic mucosa samples. The units are arbitrary, and NRD1 mRNA expression was calculated by standardization of the expression in non-neoplastic mucosa sample of case 3 to 1.0. (c) Nardilysin protein expression level in four ESCC tissue samples and their corresponding non-neoplastic mucosa samples analyzed in Figure1b. T, Tumor; N, non-neoplastic mucosa.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4317882&req=5

fig01: Quantitative reverse transcription–polymerase chain reaction (qRT-PCR) analysis of NRD1 mRNA and Western blot analysis of nardilysin protein in normal tissue samples, esophageal cancer cell lines, and esophageal squamous cell carcinoma (ESCC) tissue samples. (a) mRNA expression level of NRD1 in 15 types of normal tissue samples, six esophageal cancer cell lines, and two ESCC tissue samples. The units are arbitrary, and NRD1 mRNA expression was calculated by standardization of the expression in normal colon to 1.0. (b) mRNA expression level of NRD1 in four ESCC tissue samples and their non-neoplastic mucosa samples. The units are arbitrary, and NRD1 mRNA expression was calculated by standardization of the expression in non-neoplastic mucosa sample of case 3 to 1.0. (c) Nardilysin protein expression level in four ESCC tissue samples and their corresponding non-neoplastic mucosa samples analyzed in Figure1b. T, Tumor; N, non-neoplastic mucosa.

Mentions: To identify novel biomarkers or therapeutic targets for ESCC, we reviewed a list of genes with upregulated expression in ESCC compared with normal esophagus, as identified by our SAGE analysis.9 Among the 30 most upregulated genes in ESCC, we focused on the NRD1 gene, which encodes the nardilysin protein, because expression of NRD1 has not been investigated in ESCC, and an antibody against nardilysin is commercially available. We first performed qRT-PCR analysis of NRD1 in 15 types of normal tissue samples, six esophageal cancer cell lines, and two ESCC tissue samples (Fig.1a). Among the various normal tissue samples, abundant NRD1 expression was found in normal pancreas and skeletal muscle, as reported previously.11 Expression of NRD1 in these normal tissue samples was greatest in skeletal muscle; however, expression of NRD1 in ESCC tissue samples was even greater than in skeletal muscle.


NRD1, which encodes nardilysin protein, promotes esophageal cancer cell invasion through induction of MMP2 and MMP3 expression.

Uraoka N, Oue N, Sakamoto N, Sentani K, Oo HZ, Naito Y, Noguchi T, Yasui W - Cancer Sci. (2013)

Quantitative reverse transcription–polymerase chain reaction (qRT-PCR) analysis of NRD1 mRNA and Western blot analysis of nardilysin protein in normal tissue samples, esophageal cancer cell lines, and esophageal squamous cell carcinoma (ESCC) tissue samples. (a) mRNA expression level of NRD1 in 15 types of normal tissue samples, six esophageal cancer cell lines, and two ESCC tissue samples. The units are arbitrary, and NRD1 mRNA expression was calculated by standardization of the expression in normal colon to 1.0. (b) mRNA expression level of NRD1 in four ESCC tissue samples and their non-neoplastic mucosa samples. The units are arbitrary, and NRD1 mRNA expression was calculated by standardization of the expression in non-neoplastic mucosa sample of case 3 to 1.0. (c) Nardilysin protein expression level in four ESCC tissue samples and their corresponding non-neoplastic mucosa samples analyzed in Figure1b. T, Tumor; N, non-neoplastic mucosa.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4317882&req=5

fig01: Quantitative reverse transcription–polymerase chain reaction (qRT-PCR) analysis of NRD1 mRNA and Western blot analysis of nardilysin protein in normal tissue samples, esophageal cancer cell lines, and esophageal squamous cell carcinoma (ESCC) tissue samples. (a) mRNA expression level of NRD1 in 15 types of normal tissue samples, six esophageal cancer cell lines, and two ESCC tissue samples. The units are arbitrary, and NRD1 mRNA expression was calculated by standardization of the expression in normal colon to 1.0. (b) mRNA expression level of NRD1 in four ESCC tissue samples and their non-neoplastic mucosa samples. The units are arbitrary, and NRD1 mRNA expression was calculated by standardization of the expression in non-neoplastic mucosa sample of case 3 to 1.0. (c) Nardilysin protein expression level in four ESCC tissue samples and their corresponding non-neoplastic mucosa samples analyzed in Figure1b. T, Tumor; N, non-neoplastic mucosa.
Mentions: To identify novel biomarkers or therapeutic targets for ESCC, we reviewed a list of genes with upregulated expression in ESCC compared with normal esophagus, as identified by our SAGE analysis.9 Among the 30 most upregulated genes in ESCC, we focused on the NRD1 gene, which encodes the nardilysin protein, because expression of NRD1 has not been investigated in ESCC, and an antibody against nardilysin is commercially available. We first performed qRT-PCR analysis of NRD1 in 15 types of normal tissue samples, six esophageal cancer cell lines, and two ESCC tissue samples (Fig.1a). Among the various normal tissue samples, abundant NRD1 expression was found in normal pancreas and skeletal muscle, as reported previously.11 Expression of NRD1 in these normal tissue samples was greatest in skeletal muscle; however, expression of NRD1 in ESCC tissue samples was even greater than in skeletal muscle.

Bottom Line: Furthermore, nardilysin expression was significantly associated with poorer prognosis (P = 0.0258).The invasiveness of NRD1-knockdown TE1 and TE5 esophageal cancer cell lines was less than that of the negative control siRNA-transfected cell lines.Expression of MMP2 and MMP3 mRNA was significantly lower in NRD1-knockdown TE5 cells than in negative control siRNA-transfected cells.

View Article: PubMed Central - PubMed

Affiliation: Department of Molecular Pathology, Hiroshima University Institute of Biomedical and Health Sciences, Hiroshima, Japan.

Show MeSH
Related in: MedlinePlus